Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer Offering $500M in Senior Notes to Fund Caliper Purchase

NEW YORK (GenomeWeb News) – PerkinElmer today announced the pricing of a $500 million offering to be used in part to fund its $600 million purchase of Caliper Life Sciences.

The senior notes carry an aggregate principal amount of 5 percent and are due 2021 at an issue price of 99.372 percent of the principal amount. The issuance of the notes is expected to close Oct. 25. The notes will pay interest on a semi-annual basis.

The joint book-running managers on the offering are Merrill Lynch, Pierce, Fenner & Smith; Barclays Capital; and Deutsche Bank Securities.

The purchase of Caliper was announced last month. Earlier this week, the deal cleared regulatory hurdles in the US and Germany and now awaits shareholder approval and other conditions.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.